Research on CBD for Chron’s Disease

(2017) Low-Dose Cannabidiol Is Safe but Not Effective in the Treatment for Crohn’s Disease, a Randomized Controlled Trial.

(2017) Cannabinoids for treating inflammatory bowel diseases: where are we and where do we go?

(2016) An Orally Active Cannabis Extract with High Content in Cannabidiol attenuates Chemically-induced Intestinal Inflammation and Hypermotility in the Mouse.

(2016) Medical use of cannabis products: Lessons to be learned from Israel and Canada.

(2015) Israel: Research without prejudice.

(2015) Endocannabinoids and the Digestive Tract and Bladder in Health and Disease.

(2013) Cannabinoid-induced autophagy regulates suppressor of cytokine signaling-3 in intestinal epithelium.

(2014) Physiological intestinal oxygen modulates the Caco-2 cell model and increases sensitivity to the phytocannabinoid cannabidiol.

(2014) Interleukin 17A evoked mucosal damage is attenuated by cannabidiol and anandamide in a human colonic explant model.

(2014) Cannabis for inflammatory bowel disease.

(2013) Cannabis induces a clinical response in patients with Crohn’s disease: a prospective placebo-controlled study.

(2013) A role for O-1602 and G protein-coupled receptor GPR55 in the control of colonic motility in mice.

(2013) Cannabidiol in inflammatory bowel diseases: a brief overview.

(2011) Cannabidiol reduces intestinal inflammation through the control of neuroimmune axis.

(2011) The effects of cannabidiolic acid and cannabidiol on contractility of the gastrointestinal tract of Suncus murinus.

(2011) Cannabinoids mediate opposing effects on inflammation-induced intestinal permeability.

(2011) Cannabinoid actions at TRPV channels: effects on TRPV3 and TRPV4 and their potential relevance to gastrointestinal inflammation.

(2011) A novel CB receptor GPR55 and its ligands are involved in regulation of gut movement in rodents.

(2010) Pharmacological effects of cannabinoids on the Caco-2 cell culture model of intestinal permeability.

(2010) The effects of Delta-tetrahydrocannabinol and cannabidiol alone and in combination on damage, inflammation and in vitro motility disturbances in rat colitis.

(2009) Cannabidiol, a safe and non-psychotropic ingredient of the marijuana plant Cannabis sativa, is protective in a murine model of colitis.

(2008) Cannabidiol, extracted from Cannabis sativa, selectively inhibits inflammatory hypermotility in mice.

(2008) Effect of cannabidiol on sepsis-induced motility disturbances in mice: involvement of CB receptors and fatty acid amide hydrolase.

(1989) Psychoactive cannabinoids reduce gastrointestinal propulsion and motility in rodents.

(1975) Effects of 7-hydroxy-delta-6-tetrahydrocannabinol and some related cannabinoids on the guinea pig isolated ileum.